ISSN : 2146-3123
E-ISSN : 2146-3131

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
Atakan Demir1, Nil Molinas Mandel2, Semra Paydas3, Gökhan Demir1, Özlem Er1, Nazım Serdal Turhal4, Sevil Bavbek5, Yeşim Eralp1, Pınar Mualla Saip6, Emine Nilüfer Güler7, Adnan Aydıner6, Başak Oyan Uluç1, Sadettin Kılıçkap7, Necdet Üskent4, Nuri Karadurmuş8, Mehmet Ali Kaplan9, Mustafa Teoman Yanmaz10, Hacer Demir11, Özkan Alan12, Taner Korkmaz1, Polat Olgun13, Özlem Sönmez Uysal1, Kadri Altundağ14, Şeyda Gündüz15, Meral Günaldı16, Murat Sarı5, İsmail Beypınar11, Gül Başaran1
1Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
2Clinic of Oncology, American Hospital, İstanbul, Turkey
3Department of Medical Oncology, Çukurova University School of Medicine, Adana, Turkey
4Clinic of Oncology, Anadolu Medical Center Hospital, Kocaeli, Turkey
5Self-employed, İstanbul, Turkey
6Department of Medical Oncology, İstanbul University Oncology Institute, İstanbul, Turkey
7Department of Medical Oncology, Hacettepe University School of Medicine, Ankara, Turkey
8Clinic of Medical Oncology T.C. Ministry of Health Gülhane Training and Research Hospital, Ankara, Turkey
9Department of Medical Oncology, Dicle University School of Medicine, Diyarbakır, Turkey
10Şişli Memorial Hospital, İstanbul, Turkey
11Department of Medical Oncology Afyon Kocatepe University School of Medicine, Afyon, Turkey
12Tekirdağ State Hospital, Tekirdağ, Turkey
13Near East University Hospital, Lefkoşa, TRNC
14Self-employed, Ankara, Turkey
15Antalya Memorial Hospital, Antalya, Turkey
16Clinic of Medical Oncology, Florya Medical Park Hospital, İstanbul, Turkey
DOI : 10.4274/balkanmedj.galenos.2020.2019.11.143
Pages : 104-107

Abstract

Background: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood.
Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed.
Study Design: Multicenter retrospective observational cohort study.
Methods: In this retrospective observational cohort study, we included 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2− metastatic breast cancer.
Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only six patients (14%).
Conclusion: The efficacy of palbociclib among heavily treated hormone receptor-positive/HER2− patients with advanced breast cancer was acceptable in terms of clinical benefit, and it was generally well tolerated among this population.

Keywords : Breast cancer, CDK4/6 inhibitors, palbociclib
Viewed : 565
Downloaded : 466